

Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

January 6, 2023 – release at 7:30 am CET
Sophia Antipolis, France

Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2022:

- 288,965 shares
- €22,074.60

- Number of executions on buy side on semester: 274
- Number of executions on sell side on semester: 195
- Traded volume on buy side on semester: 155,703 shares for €262,378.38
- Traded volume on sell side on semester: 100,347 shares for €178,155.02

As a reminder:

- the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:
 - 233,609 shares
 - €106,207.47

 - Number of executions on buy side on semester: 526
 - Number of executions on sell side on semester: 571
 - Traded volume on buy side on semester: 336,531 shares for €706,259.94
 - Traded volume on sell side on semester: 314,889 shares for €660,405.27

- the following resources appeared on the liquidity account when the activity started:
 - shares
 - €500,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	274	155,703	262,378.38	195	100,347	178,155.02
01/07/2022	9	8,000	13,200.00	5	2,265	3,850.50
04/07/2022	-	-	-	1	1,000	1,720.00
05/07/2022	1	1,000	1,700.00	8	2,999	5,248.25
06/07/2022	-	-	-	2	1,000	1,760.00
07/07/2022	-	-	-	7	3,000	5,400.00
08/07/2022	-	-	-	2	1,000	1,840.00
11/07/2022	-	-	-	4	2,972	5,587.36
12/07/2022	3	1,000	1,860.00	-	-	-
13/07/2022	3	2,000	3,660.00	1	1,000	1,840.00
18/07/2022	-	-	-	6	2,000	3,740.00
19/07/2022	4	4,000	7,320.00	2	201	373.86
20/07/2022	-	-	-	5	1,799	3,382.12
21/07/2022	6	1,364	2,496.12	-	-	-
22/07/2022	1	636	1,157.52	1	12	22.32
25/07/2022	-	-	-	1	322	592.48
26/07/2022	-	-	-	1	1	1.84
27/07/2022	-	-	-	1	324	596.16
28/07/2022	-	-	-	1	322	592.48
29/07/2022	-	-	-	1	31	57.04
05/08/2022	1	513	933.66	2	41	76.26
08/08/2022	-	-	-	8	3,947	7,459.83
09/08/2022	-	-	-	2	1,100	2,134.00
10/08/2022	-	-	-	8	2,900	5,684.00
12/08/2022	-	-	-	1	292	584.00
15/08/2022	-	-	-	1	708	1,416.00
16/08/2022	-	-	-	5	4,000	8,200.00
17/08/2022	4	2,000	4,060.00	-	-	-
18/08/2022	4	3,000	6,000.00	1	2,000	4,100.00
19/08/2022	1	84	168.00	-	-	-
22/08/2022	5	2,946	5,921.46	-	-	-
23/08/2022	2	970	1,940.00	-	-	-
24/08/2022	-	-	-	1	2,000	4,000.00
25/08/2022	2	3,500	6,895.00	1	209	418.00
26/08/2022	6	2,500	4,950.00	1	1,291	2,582.00
29/08/2022	3	4,000	7,720.00	-	-	-
30/08/2022	-	-	-	2	1,000	1,940.00
01/09/2022	6	3,001	5,641.88	1	1	1.93
05/09/2022	-	-	-	1	1,000	1,880.00

	Achats		
	Nombre de transactions	Nombre de titres	Capitaux en EUR
Total	274	155,703	262,378.38
06/09/2022	2	1,177	2,189.22
07/09/2022	1	823	1,514.32
08/09/2022	-	-	-
09/09/2022	-	-	-
12/09/2022	1	1,000	1,960.00
14/09/2022	10	4,000	7,840.00
15/09/2022	3	1,000	1,940.00
16/09/2022	5	4,000	7,640.00
19/09/2022	2	1,000	1,880.00
20/09/2022	1	1,000	1,940.00
21/09/2022	3	3,000	5,730.00
22/09/2022	2	1,000	1,880.00
23/09/2022	8	3,487	6,381.21
26/09/2022	10	4,000	7,000.00
27/09/2022	1	1,000	1,700.00
28/09/2022	2	1,102	1,895.44
29/09/2022	1	898	1,526.60
30/09/2022	-	-	-
03/10/2022	1	1,000	1,680.00
04/10/2022	-	-	-
06/10/2022	1	1	1.78
07/10/2022	2	255	459.00
11/10/2022	2	578	1,040.40
12/10/2022	-	-	-
13/10/2022	1	1,000	1,830.00
14/10/2022	1	500	925.00
17/10/2022	1	1,000	1,870.00
18/10/2022	-	-	-
19/10/2022	-	-	-
21/10/2022	3	1,200	2,412.00
24/10/2022	-	-	-
26/10/2022	2	1,014	2,068.56
27/10/2022	8	3,986	7,932.14
28/10/2022	2	354	693.84
31/10/2022	30	15,813	29,254.05
01/11/2022	5	3,000	5,220.00
02/11/2022	-	-	-
08/11/2022	1	1,000	1,720.00
09/11/2022	-	-	-

	Ventes		
	Nombre de transactions	Nombre de titres	Capitaux en EUR
Total	195	100,347	178,155.02
	-	-	-
	5	2,000	3,800.00
	2	1,000	1,940.00
	3	2,000	3,980.00
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	2	4,000	7,760.00
	-	-	-
	1	1	1.96
	-	-	-
	-	-	-
	-	-	-
	2	1,000	1,760.00
	-	-	-
	-	-	-
	4	1,000	1,720.00
	1	842	1,465.08
	4	3,158	5,621.24
	3	1,001	1,821.82
	-	-	-
	-	-	-
	2	1,000	1,840.00
	2	1,020	1,897.20
	1	1,000	1,880.00
	2	2,000	3,820.00
	7	2,045	3,987.75
	10	5,954	11,788.92
	-	-	-
	7	4,000	8,160.00
	-	-	-
	-	-	-
	2	1,000	2,000.00
	5	3,000	6,090.00
	-	-	-
	4	3,000	5,400.00
	-	-	-
	1	1	1.74

	Achats			Ventes		
	Nombre de transactions	Nombre de titres	Capitaux en EUR	Nombre de transactions	Nombre de titres	Capitaux en EUR
Total	274	155,703	262,378.38	195	100,347	178,155.02
10/11/2022	2	1,000	1,700.00	-	-	-
15/11/2022	-	-	-	4	999	1,738.26
17/11/2022	3	1,000	1,720.00	-	-	-
18/11/2022	2	657	1,116.90	-	-	-
21/11/2022	1	843	1,433.10	1	24	41.52
22/11/2022	24	14,000	22,260.00	-	-	-
23/11/2022	3	3,000	4,440.00	-	-	-
24/11/2022	2	1,000	1,440.00	-	-	-
25/11/2022	1	1,000	1,420.00	-	-	-
28/11/2022	3	2,000	2,780.00	-	-	-
29/11/2022	6	3,000	3,990.00	-	-	-
30/11/2022	2	2,000	2,540.00	1	1,000	1,320.00
01/12/2022	2	1,500	1,890.00	-	-	-
02/12/2022	1	1,000	1,280.00	2	1,000	1,300.00
05/12/2022	1	1,000	1,300.00	5	4,000	5,480.00
06/12/2022	4	4,000	5,160.00	-	-	-
07/12/2022	2	2,000	2,500.00	-	-	-
08/12/2022	2	1,000	1,240.00	-	-	-
09/12/2022	1	1,000	1,220.00	2	1,000	1,260.00
12/12/2022	1	1,000	1,200.00	-	-	-
13/12/2022	2	1,001	1,181.18	4	2,000	2,420.00
14/12/2022	3	1,972	2,307.24	1	100	119.00
15/12/2022	4	1,028	1,202.76	2	200	238.00
16/12/2022	1	1,000	1,160.00	-	-	-
19/12/2022	20	3,000	3,450.00	-	-	-
20/12/2022	6	5,000	5,600.00	3	2,000	2,240.00
21/12/2022	2	1,000	1,100.00	-	-	-
22/12/2022	-	-	-	2	2,000	2,240.00
23/12/2022	-	-	-	8	3,000	3,360.00
27/12/2022	-	-	-	6	2,265	2,582.10

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also conducting research on NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in conditions. NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals for topical ocular application for dry eye disease, is being developed by Ocumension Therapeutics in China under an exclusive license agreement and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyeavance Pharmaceuticals, LLC (a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment C: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Eric Yoo	Paris, France
Edison Investment Research	Pooya Hemami	London, UK
H.C. Wainwright & Co	Yi Chen	New York, U.S.
Kepler Cheuvreux	Arsene Guekam	Paris, France



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Nicox

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media

United States & Europe
LifeSci Advisors, LLC
Sandy von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2021' filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022, in its first amendment filed with the AMF on May 19, 2022, in the 2nd chapter of its second amendment filed with the AMF on November 22, 2022 and in the 2nd chapter of the Securities note filed with the AMF on November 22, 2022 which are available on Nicox's website (www.nicox.com).

Nicox SA

Drakkar 2 - Bât D
2405 route des Dolines
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99